Compare, Analyse VENUS REMEDIES with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   TEVA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TEVA PHARMA
Dec-13
VENUS REMEDIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1263,117-   
Low Rs612,708-   
Sales per share (Unadj.) Rs301.81,788.7-  
Earnings per share (Unadj.) Rs-24.9111.7-  
Cash flow per share (Unadj.) Rs2.5256.3-  
Dividends per share (Unadj.) Rs097.82-  
Dividend yield (eoy) %03.4 0.0%  
Book value per share (Unadj.) Rs293.31,986.9-  
Shares outstanding (eoy) m12.34848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.6 19.0%   
Avg P/E ratio x-3.826.1 -14.4%  
P/CF ratio (eoy) x36.711.4 323.4%  
Price / Book Value ratio x0.31.5 21.8%  
Dividend payout %087.5 0.0%   
Avg Mkt Cap Rs m1,1542,469,486 0.0%   
No. of employees `0000.944.9 2.1%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.133,748.9 11.9%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.82,108.3 -15.7%   
INCOME DATA
Net Sales Rs m3,7241,516,846 0.2%  
Other income Rs m230-   
Total revenues Rs m3,7471,516,846 0.2%   
Gross profit Rs m395415,389 0.1%  
Depreciation Rs m338122,608 0.3%   
Interest Rs m35429,793 1.2%   
Profit before tax Rs m-275262,988 -0.1%   
Minority Interest Rs m01,195 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-172,637 0.0%   
Tax Rs m32-3,211 -1.0%   
Profit after tax Rs m-30794,756 -0.3%  
Gross profit margin %10.627.4 38.7%  
Effective tax rate %-11.5-1.2 940.2%   
Net profit margin %-8.26.2 -131.9%  
BALANCE SHEET DATA
Current assets Rs m2,6381,024,472 0.3%   
Current liabilities Rs m2,305893,427 0.3%   
Net working cap to sales %8.98.6 103.5%  
Current ratio x1.11.1 99.8%  
Inventory Days Days13591 149.2%  
Debtors Days Days4696 48.3%  
Net fixed assets Rs m4,871495,435 1.0%   
Share capital Rs m1233,734 3.3%   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,6191,684,929 0.2%   
Long term debt Rs m1,374775,597 0.2%   
Total assets Rs m7,5093,466,480 0.2%  
Interest coverage x0.29.8 2.3%   
Debt to equity ratio x0.40.5 82.5%  
Sales to assets ratio x0.50.4 113.3%   
Return on assets %0.63.6 17.6%  
Return on equity %-8.55.6 -150.8%  
Return on capital %1.64.9 32.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m514241,707 0.2%  
From Investments Rs m-123-85,646 0.1%  
From Financial Activity Rs m-387-289,944 0.1%  
Net Cashflow Rs m4-133,883 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 74.67 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare VENUS REMEDIES With: SANOFI INDIA  DISHMAN PHARMA  ALEMBIC  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Equity Mutual Fund Inflows in March, RBI's First Purchase Under G-SAP 1.0, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended marginally lower on Friday last week. At the closing bell on Friday, the BSE Sensex stood lower by 154 points (down by 0.3%).

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market (Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers (Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

India's Revival: A Once-in-a-generation Wealth Making Opportunity
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

VENUS REMEDIES SHARE PRICE


Apr 9, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - JUBILANT PHARMOVA COMPARISON

COMPARE VENUS REMEDIES WITH

FEATURED VIDEOS

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

Kalyan Jewellers IPO: An Honest View

More Featured Videos

MARKET STATS